EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Membranous nephropathy treatment standard

Yeshwanter Radhakrishnan, Ladan Zand, Sanjeev Sethi iD, Fernando C Fervenza iD

Nephrology Dialysis Transplantation · 28.02.2024 · 39 (3) · 403-413

DOI: 10.1093/ndt/gfad225 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 02.11.2023. Verfasst von Yeshwanter Radhakrishnan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: Mayo Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Membranous nephropathy (MN) is characterized by deposition of immune complexes leading to thickening of glomerular basement membranes. Over time, the understanding of MN has evolved, with the identification of specific autoantibodies against novel podocyte antigens and the unraveling of intricate pathogenic pathways. Although the anti-CD20 monoclonal antibody rituximab is favored as part of the initial therapy in MN, a subgroup of MN patients may be resistant to rituximab necessitating the use of alternative agents such as cytotoxic therapies. In addition, newer agents such as novel anti-CD20 monoclonal antibodies, therapies targeting the CD38-positive plasma cells and anti-complement therapy are being studied in patients who are resistant to traditional treatment strategies. This manuscript furnishes a review of the novel developments in the pathophysiology of MN including the identification of target antigens and current treatment standards for MN, concentrating on evidenced-based interventions designed to attain remission and to prevent disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousHumansRituximabAntibodies, MonoclonalAutoantibodiesAntigen-Antibody ComplexReceptors, Phospholipase A2

Stichwörter der Autor:innen

cyclophosphamidecyclosporinemembranous nephropathyrituximabtacrolimus

Substanzen

RituximabAntibodies, MonoclonalAutoantibodiesAntigen-Antibody ComplexReceptors, Phospholipase A2

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Sanjeev Sethi, Fernando C Fervenza

Förderung

  • Mayo Foundation

Zitieren

APA

Radhakrishnan, Y., Zand, L., Sethi, S., & Fervenza, F. C. (2024). Membranous nephropathy treatment standard. Nephrology Dialysis Transplantation, 39(3), 403-413. https://doi.org/10.1093/ndt/gfad225

Vancouver

Radhakrishnan Y, Zand L, Sethi S, Fervenza FC. Membranous nephropathy treatment standard. Nephrology Dialysis Transplantation. 2024;39(3):403-413. doi:10.1093/ndt/gfad225

BibTeX
@article{Radhakrishnan2024,
  author = {Radhakrishnan, Yeshwanter and Zand, Ladan and Sethi, Sanjeev and Fervenza, Fernando C},
  title = {Membranous nephropathy treatment standard},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  volume = {39},
  number = {3},
  pages = {403--413},
  doi = {10.1093/ndt/gfad225}
}
Kostenlos starten →